The objective of this project is the development of a multivalent vaccine against the meningococcal serogroups responsible for the majority of cases worldwide (A, B, C, Y, W, X), which is competitive in the current market, using conjugated polysaccharides or combinations thereof with proteins derived from the bacteria. These vaccine combinations have been highly immunogenic, mainly through the measurement of the induced bactericidal response.